Trending
- TV presenter cuts the ribbon at Medray HQ
- Esaote reflects innovation and empathy through new identity
- Former chair Dobson takes up role as AXREM director of government affairs
- Radiology AI marketplace CARPL.ai aims to accelerate adoption
- How to start your breast AI journey?
- Walk the Walk grant helps cancer charity provide more patient support
- AI tools enable secure monetisation for medical imaging data
- Compact space, big possibilities
- Latest adjustable height trolley from Wardray offers increased weight capacity
- AXREM reaches membership milestone
The contribution of hybrid imaging to radionuclide therapy
Author(s): Carla Aberu, Paul Gape, Jan Taprogge, Glen Fluxx
Hospital: The Royal Marsden Hospital, The Institute of Cancer Research
Reference: RAD Magazine, 47, 556, 19
Excerpt: Radionuclide therapy is a rapidly evolving field considered a safe and effective targeted approach to treating many types of cancer. Radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate at the site of treatment by physiological mechanisms. Almost all radionuclides used in radionuclide therapy emit photons that can be imaged, enabling non-invasive visualisation of the biodistribution of the therapeutic agent. The combination of functional imaging in nuclear medicine (SPECT, PET) with anatomical imaging in CT, in what is referred to as hybrid imaging, provides undoubted diagnostic value. After many decades of little growth, a dramatic increase in radiotherapeutics heralds what is promising to be a step change in this area of cancer management.